Wuhan General Gr Chn
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $3.05 million
- Book Value:
- Revenue TTM:
- $80.38 million
- Operating Margin TTM:
- Gross Profit TTM:
- $14.54 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Wuhan General Gr Chn had its IPO on 1998-04-24 under the ticker symbol WUHN.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Wuhan General Gr Chn has a staff strength of 700 employees.
Shares of Wuhan General Gr Chn opened at $0.02 at the start of the last trading session i.e. 2023-03-31.
The stocks traded within a range of $0.02 - $0.02, and closed at $0.02.
This is a 0% increase from the previous day's closing price.
A total volume of 0 shares were traded at the close of the day’s session.
In the last one week, shares of Wuhan General Gr Chn have increased by 0%.
Wuhan General Gr Chn's Key Ratios
Wuhan General Gr Chn has a market cap of $3.05 million, indicating a price to book ratio of 0.0411 and a price to sales ratio of 0.0478.
In the last 12-months Wuhan General Gr Chn’s revenue was $80.38 million with a gross profit of $14.54 million and an EBITDA of $379915. The EBITDA ratio measures Wuhan General Gr Chn's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Wuhan General Gr Chn’s operating margin was -2.77% while its return on assets stood at -0.5% with a return of equity of -8.78%.
In Q4, Wuhan General Gr Chn’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Wuhan General Gr Chn’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.03 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Wuhan General Gr Chn’s profitability.
Wuhan General Gr Chn stock is trading at a EV to sales ratio of 0.038 and a EV to EBITDA ratio of 0.9595. Its price to sales ratio in the trailing 12-months stood at 0.0478.
Wuhan General Gr Chn stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $286.58 million
- Total Liabilities
- $179.25 million
- Operating Cash Flow
- $2.14 million
- Capital Expenditure
- $17.69 million
- Dividend Payout Ratio
Wuhan General Gr Chn ended 2023 with $286.58 million in total assets and $0 in total liabilities. Its intangible assets were valued at $286.58 million while shareholder equity stood at $76.06 million.
Wuhan General Gr Chn ended 2023 with $0 in deferred long-term liabilities, $179.25 million in other current liabilities, 3251.00 in common stock, $14.61 million in retained earnings and $0 in goodwill. Its cash balance stood at $18.79 million and cash and short-term investments were $0. The company’s total short-term debt was $118,797,991 while long-term debt stood at $0.
Wuhan General Gr Chn’s total current assets stands at $197.40 million while long-term investments were $0 and short-term investments were $12.10 million. Its net receivables were $86.24 million compared to accounts payable of $17.54 million and inventory worth $49.19 million.
In 2023, Wuhan General Gr Chn's operating cash flow was $2.14 million while its capital expenditure stood at $17.69 million.
Comparatively, Wuhan General Gr Chn paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Wuhan General Gr Chn stock is currently trading at $0.02 per share. It touched a 52-week high of $0.52 and a 52-week low of $0.52. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.03 and 200-day moving average was $0.07 The short ratio stood at 0.15 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 0.4% are held by institutions.
Frequently Asked Questions About Wuhan General Gr Chn
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Wuhan General Group (China), Inc., through its subsidiaries, researches, develops, and commercializes a range of cannabidiol (CBD)-based products under the Dr. AnnaRx brand for pharmacies. It also focuses on exploring and developing other indications for psilocybin new therapies that will enable patients who suffer from mental illness. The company offers its products for medical applications, including cancer, mental disorders, chronic pain, and others. Wuhan General Group (China), Inc. is headquartered in Pointe-Claire, Canada.